Latest News

Cellink AB to take-over Discover Echo Inc

© Discover Echo Inc.


by tg

Swedish Cellink AB has announced a bid of $110m to take over all shares of Discover Echo Inc., 11% of which to be paid in newly issued shares.

San Diego-based Discover Echo Inc. is  a specialist for unique hybrid automated microscopes that easily transform between upright (for viewing glass slides) and inverted configurations (for viewing live samples in petri dishes and well plates), merging the capabilities of multiple instruments into one. Cellink expects the company, which has a subsidiary in the UK, to grow 65% in 2021 and generate about $20m in revenues.

Discover Echo has a large growth potential in the bioprocessing industry where the CELLINK Group is a well-known supplier and has the ability to accelerate Discover Echo’s penetration in this sector. The US company has improved the usability of their microscopes by replacing traditional eyepieces with ultra high-resolution touchscreen displays and offering an intuitive software app that advances the workflow of acquiring, sharing, and analysing images.

"With the strategic acquisition of Discover Echo, we further strengthen our position within our Biosciences segment and we further complement our existing bioconvergence products and capture strong cross-selling synergies,” said Erik Gatenholm, CEO of Cellink AB.

Promethera bags €20m for liver failure treatment

The Belgian cell therapy specialist was supported by an investor consortium from Belgium, Germany and China. The Hongkong company Tata Health...

Foundation launches Harvard research hub

The foundation and the Broad Institute have joined up to launch the Novo Nordisk Foundation Center for Genomic Mechanisms of Disease, an initiative...

Data protection rules may block medical progress

On Monday, EU data protection agencies asked for a “general ban” on the  “recognition of faces, gait, fingerprints, DNA, voice, keystrokes and...

AstraZeneca puts €307m in Irish Alexion plant

Alexion's newly created modular API facility will complement an existing packaging site in Dublin. It is designed to produce linkers and toxic...

Bayer: Peptide deal with Gubra

The partnership utilises Gubra’s machine learning-based peptide drug discovery platform for fast screening and identification of potent therapeutic...

US$21m for microbiome therapies

Scottish biopharmaceutical company EnteroBiotix is focussed on addressing a wide range of diseases by enhancing the diversity of the microbiome. Now,...

Abcam to acquire BioVision for $340m

With BioVision’s acquisition Abcam plc complements its portfolio of research tools to support research, diagnostics, and drug discovery, particularly...